[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020; 382(8):727-33. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
[2] Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgraduate medical journal. 2021; 97(1147):312-20.
[DOI:10.1136/postgradmedj-2020-138577] [PMID] [PMCID]
[3] Alimolaie A. [A review of coronavirus disease-2019 (COVID-19)(Persian)]. Iranian Journal of Biology. 2020; 3(6):152-7. [Link]
[4] Fahmi I. World Health Organization coronavirus disease 2019 (Covid-19) situation report. DroneEmprit. 2019. [Link] [5] Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-20. [DOI:10.1038/s41586-020-2180-5] [PMID]
[6] Kakodkar P, Kaka N, Baig M. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus. 2020; 12(4):e7560. [DOI:10.7759/cureus.7560] [PMID] [PMCID]
[7] Fung TS, Liu DX. Post-translational modifications of coronavirus proteins: roles and function. Future virology. 2018; 13(6):430-05. [DOI:10.2217/fvl-2018-0008] [PMID]
[8] Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020; 369 (6501):330-3. [DOI:10.1126/science.abb9983] [PMID] [PMCID] [9] Chen W, Hui Z, Ren X, Luo Y, Shu J, Yu H, Li Z. The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 Coronavirus. bioRxiv. 2020. [DOI:10.1101/2020.12.01.406025]
[10] Shin Y-J, König-Beihammer J, Vavra U, Schwestka J, Kienzl NF, Klausberger M, Laurent E, Grünwald-Gruber C, Vierlinger K, Hofner M, Margolin E. N-glycosylation of the SARS-CoV-2 receptor binding domain is important for functional expression in plants. Frontiers in Plant Science. 2021; 12: 689104.
[DOI:10.3389/fpls.2021.689104] [PMID]
[11] Almehdi AM, Khoder G, Alchakee AS, Alsayyid AT, Sarg NH, Soliman SS. SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies. Infection. 2021; 49(5):855-76. [DOI: 10.1007/s15010-021-01677-8] [PMID] [PMCID]
[12] Prahlad J, Struble LR, Lutz WE, Wallin SA, Khurana S, Schnaubelt A, et al. Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain. bioRxiv. 2021: 2021-02. [DOI:10.1101/2021.02.03. 429601]
[13] Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines. 2022; 10(1):96.
[DOI:10.3390/vaccines10010096] [PMID] [PMCID]
[14] Verissimo CDM, O'brien C, Corrales JL, Dorey A, Cwiklinski K, Lalor R, Doyle JM, Field S, Masterson C, Martinez ER, Hughes G. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology & Infection. 2021; 149: e140. [DOI:10.1017/S09 50268821001308] [PMID] [PMCID]
[15] Verissimo CDM, Lopez-Corrales J, Dorey AL, Cwiklinski K, Lalor R, Calvani NED, Jewhurst HL, Flaus A, Doyle S, Dalton JP. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-Like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system. Epidemiology & Infection. 2022; 150:e128. [DOI:10.1017/S0950268822001078] [PMID] [PMCID]
)